Roche buys oligonucleotide partner Santaris for $250mm up front
Seven months after Roche partnered with Santaris Pharma AS on RNA disease targets, the Big Pharma acquired the private Danish biotech for $250mm up front plus up to $200mm in earn-outs.
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.